Stifel analyst needs to read patent details before commenting | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  22228 of 23273  at  6/18/2019 10:32:39 PM  by

alias geo


Stifel analyst needs to read patent details before commenting

The recent Pfizer deal should be a "tailwind boosting small and mid-size cancer company stocks thought to have good research data supporting their drugs, Stifel analyst Stephen Willey said.
Exelixis was one company that quickly came to mind, Willey said. Still, an investment might be difficult to rationalize because Exelixis might have a shorter duration of patent protection on its products, he said.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 335
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...